ReviewBoneKEy reports2013
Bone composition: relationship to bone fragility and antiosteoporotic drug effects.
Review in BoneKEy reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 143 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed, 1 synthesis or guideline pooled it, 410 citations in OpenAlex.
- Osteoglycin and Bone-a Systematic Review.Current osteoporosis reports · 2019Pooled it
- Examining the Relationships Between Bone Tissue Composition, Compositional Heterogeneity, and Fragility Fracture: A Matched Case-Controlled FTIRI Study.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016Trial
- Biomechanical, Structural, and Composition Characterization of the Vertebra-Disc Interface.JOR spine · 2026Article
- Lipid nanoparticles for bone marrow-targeted RNA therapeutics.Journal of nanobiotechnology · 2026Review
- The Crucial Role of Exercise in Promoting Adolescent Bone Health.Advances in experimental medicine and biology · 2026Review
- Nanotechnology-Driven Therapeutic Potential of Raloxifene in Osteoporosis and Cancer: A Recent Review.Current pharmaceutical design · 2026Review
- Article
- Mechanistic Insights into Kaempferol's Therapeutic Effects on Postmenopausal Osteoporosis: A Proteomic and Experimental Validation in Ovariectomized Rats.Combinatorial chemistry & high throughput screening · 2026Article
- Protective Effects ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Potential metabolic records in isotope signals of chondrichthyan hard tissues.Journal of fish biology · 2025Article
- Osteoblasts sense extracellular levels of phosphate to control the local expression of phosphatases for matrix mineralisation.Bone reports · 2025Article
- Limosilactobacillus reuteri with menaquinone-7 improves bone biomechanics and microarchitecture in ovariectomized mice: preliminary study.Journal of bone and mineral metabolism · 2025Article
- Risk of bony endplate failure during vertebral fracture.Journal of the mechanical behavior of biomedical materials · 2025Article
- Article
- Decellularized Cell-Secreted Extracellular Matrices as Biomaterials for Tissue Engineering.Small science · 2025Review
- The Multifactorial Relationship Between Bone Tissue Water and Stiffness at the Proximal Femur.Calcified tissue international · 2025Article
- Risk of fragility fracture is aggravated during bone regeneration processes in osteoporotic sheep.PloS one · 2025Article
- Biomechanical perspectives on image-based hip fracture risk assessment: advances and challenges.Frontiers in endocrinology · 2025Review
- Assessment of submicron bone tissue composition in plastic-embedded samples using optical photothermal infrared (O-PTIR) spectral imaging and machine learning.Journal of structural biology: X · 2024Article
- Method for computer tomography voxel-based finite element analysis and validation with digital image correlation system.MethodsX · 2024Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The composition of a bone can be described in terms of the mineral phase, hydroxyapatite, the organic phase, which consists of collagen type I, noncollagenous proteins, other components and water. The relative proportions of these various components vary with age, site, gender, disease and treatment. Any drug therapy could change the composition of a bone. This review, however, will only address those pharmaceuticals used to treat or prevent diseases of bone: fragility fractures in particular, and the way they can alter the composition. As bone is a heterogeneous tissue, its composition must be discussed in terms of the chemical makeup, properties of its chemical constituents and their distributions in the ever-changing bone matrix. Emphasis, in this review, is placed on changes in composition as a function of age and various diseases of bone, particularly osteoporosis. It is suggested that while some of the antiosteoporotic drugs can and do modify composition, their positive effects on bone strength may be balanced by negative ones.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.